# Clinical Trial Fraud and Blockchain: Literature Summary and References
*2026-07-06 16:56 PDT*

Deep-research synthesis. Scope: (1) prevalence, case studies, and
statistical detection of clinical trial fraud; (2) proposed blockchain
methods to prevent fraud; (3) proposed blockchain methods for data
quality, integrity, and provenance. Search covered 5 angles, fetched 22
sources, extracted 71 candidate claims, and adversarially verified 25
of them (3-vote refutation panel); 23 confirmed, 2 refuted and
excluded below.

## Summary

Fraud is a documented but statistically minor contributor to clinical
trial retractions relative to plagiarism and duplicate publication,
and overall retraction rates remain very low (0.47 percent across a
large fertility/infertility corpus, 0.20 percent among RCTs
specifically). Even so, confirmed fraud cases (ESPS2, Matsuyama et
al.) show that fabrication can persist undetected for years, and that
retracted fraudulent findings continue to be cited, almost always
without acknowledgment of the retraction, long afterward.

A mature statistical toolkit exists for detecting fabricated or
falsified trial data, built on the logic that randomization should
make baseline covariates statistically similar across arms. This runs
from early t-test/F-test and digit-preference screening
(Al-Marzouki et al. 2005) through Carlisle-style combined baseline
p-value tests (2017), newer covariance-aware statistics (the L2 test,
2020), unsupervised multivariate center-monitoring scores (de Viron et
al., validated retrospectively against the confirmed ESPS2 fraud
case), and correlation-structure methods tailored to discrete or
questionnaire outcome data (Taylor, McEntegart and Stillman 2002).
Retrospective validation against ESPS2 indicates such methods could
plausibly have flagged the fraudulent center roughly a year before it
was actually discovered.

Blockchain proposals in this literature converge on the same known
integrity failures -- outcome switching, missing data, selective
reporting, and consent/audit-trail provenance -- and address them
through immutable timestamping and permissioned or hybrid
private/public ledger architectures. Distinct systems have been
proposed for fraud prevention via smart-contract protocol enforcement
(Nugent, Upton and Cimpoesu 2016; Benchoufi and Ravaud's TrialChain
concept) and for consent/access provenance specifically (BlockTrial).
All remain prototypes or proofs-of-concept rather than validated,
deployed, multi-site production systems. The literature itself
acknowledges a structural limit: blockchain cannot prevent fully
fabricated data entered in good faith by a compliant insider before it
ever reaches the chain -- it timestamps and makes tamper-evident
whatever is entered, but does not verify truth at the point of entry.

**Gaps identified by the research (not resolved by available
sources):** no verified claim in this set reports a blockchain trial
system progressing past prototype to real multi-site deployment with
outcomes; no verified claim addresses FDA/EMA/MHRA regulatory
guidance on blockchain audit trails versus 21 CFR Part 11 / GCP
electronic-record requirements; and no verified claim gives real-world
false-positive/false-negative performance of statistical monitoring
methods across many trials (as opposed to single retrospective case
studies).

## Confirmed findings

1. **Fraud is a minor share of retractions; overall rates are low.**
   In a systematic review of 39 medically-assisted-reproduction
   retractions, fraud/suspected fraud accounted for 9.3 percent (4
   cases) versus plagiarism (30.2 percent) and duplicate publication
   (25.6 percent). Overall retraction rate: 0.47 percent across
   523,067 fertility/infertility records; 0.20 percent among RCTs
   (93/45,616). Domain-specific to fertility literature; do not
   over-generalize.
   Source: [PMC10427242](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427242/)

2. **Retracted fraudulent findings keep getting cited.** A 2005 trial
   report retracted in 2008 for data falsification was still being
   cited 11 years later. Of 148 direct citations and 2,542
   second-generation citations through 2019, 96 percent (107/112
   analyzable post-retraction direct citations) never mentioned the
   retraction.
   Source: [Springer 10.1007/s11192-020-03631-1](https://link.springer.com/article/10.1007/s11192-020-03631-1)

3. **Baseline-comparison and digit-preference screening (seminal).**
   Al-Marzouki et al. (BMJ) used t-tests/F-tests on baseline
   means/variances and chi-squared tests on terminal-digit
   distributions. Applied to a suspected fraudulent diet trial (831
   CHD patients): 16 of 22 variables showed significant variance
   differences (p as low as 2e-133), and 14 of 22 variables showed
   anomalous digit preference.
   Source: [PMC1181267](https://pmc.ncbi.nlm.nih.gov/articles/PMC1181267/)

4. **Extensions carry documented pitfalls.** Carlisle's combined
   p-value method (2017), designed for continuous baseline variables,
   produces p-values wrong by orders of magnitude when naively applied
   to dichotomous variables. A newer L2 test statistic explicitly
   accounts for covariate correlation via eigenvalue decomposition of
   the covariance matrix, avoiding a naive independence assumption.
   Sources: [arXiv 2209.00131](https://arxiv.org/pdf/2209.00131),
   [PLOS ONE 10.1371/journal.pone.0239121](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0239121)

5. **Retrospective validation against a confirmed fraud case (ESPS2).**
   In ESPS2 (7,040 patients, 60 centers, 13 countries, 1989-1995),
   center #2013 (438 patients) was confirmed to have falsified
   enrollment. A retrospective Data Inconsistency Score (838 tests per
   center, weighted geometric mean of p-values, DIS >= 1.3 flags
   atypical centers at p < 0.05) ranked the known fraudulent center
   second-highest (DIS = 4.14) among five flagged centers, and showed
   detectability at roughly 25 percent of final data volume -- well
   before the actual audit timeline.
   Source: [Springer 10.1007/s43441-021-00341-5](https://link.springer.com/article/10.1007/s43441-021-00341-5)

6. **Discrete/questionnaire data need different methods.** Continuous-
   variable methods are poorly suited to categorical outcome data.
   Taylor, McEntegart and Stillman (2002, foundational) proposed a
   graphical technique and a formal randomization test premised on the
   idea that fabricated responses fail to reproduce genuine
   inter-item correlation structure, illustrated on a schizophrenia
   trial (BPRS) dataset.
   Source: [Springer 10.1177/009286150203600115](https://link.springer.com/article/10.1177/009286150203600115)

7. **Blockchain smart-contract architectures for fraud prevention.**
   Nugent, Upton and Cimpoesu (2016) proposed a hierarchical
   Regulator/Trial smart-contract system on a private, permissioned
   Ethereum blockchain targeting endpoint switching, missing data, and
   selective publication via tamper-resistant, immutable timestamped
   records. Benchoufi and Ravaud (2019) frame blockchain as providing
   "proof of trust" (time-stamping/time-ordering) rather than reliance
   on institutional trust; smart contracts automate quality checks via
   IF/THEN logic to reduce selective reporting and outcome switching.
   They cite TrialChain, a prototype using a private blockchain
   synchronized to the public Ethereum network for data-integrity
   verification.
   Sources: [PMC5357027](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357027/),
   [Frontiers in Blockchain 10.3389/fbloc.2019.00023](https://www.frontiersin.org/journals/blockchain/articles/10.3389/fbloc.2019.00023/full)

8. **Blockchain for consent and access provenance (BlockTrial).**
   A proof-of-concept Ethereum smart-contract system (Patient and
   Researcher contracts) that keeps clinical data off-chain in a
   conventional database, appends hashed query results to the chain,
   and lets patients grant/revoke researcher access -- producing a
   durable, transparent audit log of consent and data-access
   transactions distinct from the fraud-prevention focus of Nugent et
   al. and Benchoufi and Ravaud.
   Source: [PMC6320404](https://pmc.ncbi.nlm.nih.gov/articles/PMC6320404/)

9. **Structural limitation, medium confidence.** All blockchain
   proposals surveyed remain prototypes or proofs-of-concept, not
   validated deployed systems. The Benchoufi and Ravaud review
   explicitly caveats that blockchain "does not exhaust all problems"
   and cannot itself prevent fabricated data at the point of entry.
   No adoption, regulatory-acceptance, or scalability data for real
   trials were found in the verified claim set.
   Sources: [Frontiers in Blockchain](https://www.frontiersin.org/journals/blockchain/articles/10.3389/fbloc.2019.00023/full),
   [PMC6320404](https://pmc.ncbi.nlm.nih.gov/articles/PMC6320404/)

## Refuted claims (excluded from findings above)

- Claimed false-positive rates (47.0 percent at 10 variables, 54.1
  percent at 100 variables) for naive independence-assumption fraud
  screening -- refuted 0-3, could not be verified against the source.
- Claimed p-value range (near 0, to 0.64, to 0.0055) for the Fujii et
  al. dog-study data under varying correlation assumptions -- refuted
  0-3, could not be verified against the source.
  Source checked: [PLOS ONE 10.1371/journal.pone.0239121](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0239121)

## Additional sources surfaced (not independently verified above)

These appeared in the fetch phase with extracted claims but were not
selected into the top-25 verification pass. Listed for follow-up
reading, not as confirmed findings.

- Scrybe: permissioned blockchain for proof-of-provenance of clinical
  trial data, integrating IoT/wearable sensor data --
  [arXiv 2109.05649](https://arxiv.org/pdf/2109.05649)
- Hyperledger Fabric-based framework automating six clinical trial
  processes via permissioned channels and smart contracts --
  [arXiv 1902.03975](https://arxiv.org/pdf/1902.03975)
- Hyperledger Fabric pilot for informed consent and patient engagement
  in an active Phase II trial across Canadian sites (March-November
  2019; 12/36 Canadian participants across 5/8 sites enrolled via
  optional consent module) --
  [ResearchGate: Leveraging Blockchain Technology for Informed Consent](https://www.researchgate.net/publication/355226859_Leveraging_Blockchain_Technology_for_Informed_Consent_Process_and_Patient_Engagement_in_a_Clinical_Trial_Pilot)
- Private blockchain (SHA-256 append-only chaining) tested against a
  real Phase II allergen immunotherapy trial, 159 participants --
  extracted from PMC8346314 (source graded unreliable overall; treat
  this specific claim as unverified)
- JMIR Medical Informatics (2026) systematic review of blockchain
  smart contracts for clinical trial automation, proposing a system
  architecture -- [medinform.jmir.org/2026/1/e76980](https://medinform.jmir.org/2026/1/e76980)
  (source graded unreliable overall in this run; worth a manual read)
- Systematic review, "Blockchain-based solutions for clinical trial
  data management" -- [ResearchGate](https://www.researchgate.net/publication/370055724_Blockchain-based_solutions_for_clinical_trial_data_management_a_systematic_review)
  (graded unreliable in this run; worth a manual read)
- "Applications of Blockchain Technology in Clinical Trials: Review
  and Open Challenges" -- [ResearchGate](https://www.researchgate.net/publication/342967419_Applications_of_Blockchain_Technology_in_Clinical_Trials_Review_and_Open_Challenges)
  (graded unreliable in this run; worth a manual read for critiques/
  adoption-barrier content, since the automated pass found no
  extractable claims)

## Open questions for further research

- Has any blockchain-based clinical trial data-integrity system
  (TrialChain, BlockTrial, Nugent et al.'s architecture, Scrybe, or a
  successor) progressed beyond prototype to a real multi-site
  deployment with reported outcomes?
- What do FDA, EMA, and MHRA guidance documents say about
  blockchain-based trial data provenance, and is there documented
  regulatory acceptance or rejection of blockchain audit trails as
  equivalent to 21 CFR Part 11 / GCP electronic-record requirements?
- How do CRO/sponsor central statistical monitoring systems combine
  the various detection methods (baseline comparison, digit
  preference, DIS-style multivariate scores, questionnaire
  correlation) in practice, and what is their real-world false-
  positive/false-negative performance across many trials?
- Beyond the insider-fabrication limit noted by Benchoufi and Ravaud,
  what does the literature say about scalability, cost, EDC
  interoperability, GDPR/HIPAA implications of on-chain hashes, and
  permissioned-node governance? Has any paper directly compared
  blockchain architectures to non-blockchain alternatives (e.g.,
  cryptographic timestamping, centralized audit-trail systems) on
  cost-effectiveness?

## Methodology note

Generated via a multi-agent deep-research workflow: 5 parallel search
angles, 22 sources fetched and claim-extracted, top 25 claims put
through 3-vote adversarial verification (2 of 3 votes to refute), and
synthesis with confidence ratings. Sources graded "unreliable" by the
extraction pass are listed above for manual follow-up rather than
treated as verified. Several cited papers (Al-Marzouki 2005, Nugent
2016, Taylor/McEntegart/Stillman 2002, BlockTrial 2018) fall outside a
5-7 year recency window but are retained as foundational work per the
original research question; this run did not independently check
whether more recent (2023-2026) literature has superseded or
critiqued them beyond what surfaced above.

---
*Rendered on 2026-07-06 at 16:56 PDT.*<br>
*Source: ~/prj/tch/11-blockchain-curriculum/clinical-trial-fraud-blockchain-references.md*
